Pharmacovigilance – News and Features

Huang’s team showed that space-travelling muscle had metabolic changes that indicate impaired muscle regeneration and gene activities associated to age-related muscle loss called sarcopenia.

In this interview, Tola Olorunnisola, senior vice president and general manager at Avantor, delves into how AI and automation could put the Lab of the Future within our grasp, enabling scientific breakthroughs and revolutionizing the drug development process.

Drug repurposing shows promise in the treatment of retinal degenerations, according to a new study. A combination treatment incorporating three existing drugs slowed disease progression in pre-clinical retinopathy models.

Research published in Nature reveals a new pain control pathway from the cortex to the cerebellum crucial to placebo analgesia – when the expectation of pain relief leads to pain alleviation without a therapeutic intervention, such as with a drug.

In this interview, Technology Networks spoke to Dr. Martin Vollmer, biopharma program manager within the Life Science Analysis Group at Agilent, to learn about the current analytical challenges the biopharma industry faces and how they are being addressed.

Cedars-Sinai experts believe the study's findings can play a crucial role in developing healthcare policies that promote equitable access to GLP-1RA medications.

Researchers from the University of Liverpool’s Centre for Drug Safety Science have identified unpredicted T-cell immune responses to the adenoviral (Oxford/AstraZeneca and Janssen) COVID-19 vaccines.

A new AI-based method for efficient data collection could help scientists overcome complex challenges in materials discovery and design, allowing for greater precision and speed than ever before.

A new study has illustrated the different binding kinetics of isomers of doxepin, an antihistamine, which could lead to better treatments.

While responsible for saving many lives, this treatment sometimes causes cardiac damage that stiffens the heart and puts a subset of patients at risk for future heart failure.